RxDoctor Payments Data

Ashish Haryani, MD

Advanced Heart Failure and Transplant Cardiology · Elk Grove Village, ILNPI 1245556547

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,740 of the $37,819 with a category attached, or 76.0%. 26 manufacturers reported payments, led by Boehringer Ingelheim at 47.0% of the total. 2025 is the largest year on record at $14,795, 2.4 times the $6,227 reported in 2019.

$37,819in general payments, 2019–2025

Across 223 payments — averaging $169.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$18K
  • Novartis$8K
  • Abbott$5K
  • Lilly USA, LLC$4K
  • United Therapeutics Corporation$312
  • Abiomed$296
  • plus $2K from 20 others
$205,149in research payments, 2019–2025

Across 29 payments — averaging $7074.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$72K
  • Novartis$70K
  • United Therapeutics Corporation$43K
  • Sanofi US Services Inc.$13K
  • AstraZeneca$7K

What the payments were for

  • Consulting fees$7502%
  • Speaking & faculty fees$28,74076%
  • Travel & lodging$2,2266%
  • Food & beverage$6,04216%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,819 in reported general payments places this provider in the 70th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

See all advanced heart failure and transplant cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$223,911
Medicare patients
678
Services billed
2,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis29$836,723
EntrestoSacubitril/Valsartan391$582,571
JardianceEmpagliflozin421$512,379
VyndaqelTafamidis Meglumine13$295,969
EliquisApixaban188$262,610
CamzyosMavacamten19$159,150
FarxigaDapagliflozin Propanediol73$100,015
XareltoRivaroxaban34$44,095
BrilintaTicagrelor17$13,640
VeltassaPatiromer Calcium Sorbitex11$8,551
VerquvoVericiguat11$7,517
Bumetanide164$7,162
Metoprolol Succinate205$3,355
Torsemide111$2,934
Potassium Chloride165$2,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$69$1,395,302230 claims
NovartisEntresto$8,204$582,571391 claims
Boehringer IngelheimJardiance$17,763$512,379421 claims
E.r. Squibb & Sons, L.L.C.Camzyos$142$159,15019 claims
AstraZenecaFarxiga, Brilinta$219$113,65590 claims
Johnson & JohnsonXarelto$46$44,09534 claims
MerckVerquvo$182$7,51711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

Other advanced heart failure and transplant cardiology in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →